Immune Thrombocytopenia in the United States: Epidemiology & Impact
Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by low platelet counts and increased bleeding risk. This comprehensive analysis examines the epidemiology, clinical presentation, and economic burden of ITP across the United States based on current research through 2025.
Incidence, Prevalence & Clinical Characteristics
ITP affects approximately 20,000 new individuals annually in the U.S., with prevalence ranging from 9-23.6 per 100,000 persons. Women are disproportionately affected with a 1.9:1 female-to-male ratio. While 70-80% of pediatric cases resolve spontaneously, 60-70% of adult cases become chronic, with lower remission rates of 10-20%.
Treatment Landscape & Economic Impact

$400+ Million
Annual nationwide healthcare expenditure
$16,476
Average cost per hospitalization
$10,000-$50,000
Annual cost for second-line therapies
First-line treatments include corticosteroids, IVIG, and anti-D immunoglobulin. Second-line options for chronic cases include rituximab, thrombopoietin receptor agonists, and fostamatinib. Splenectomy usage has declined from 30% in the 1990s to under 10% today. Treatment access varies significantly based on insurance status, with disparities affecting rural and low-income populations.